Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib in Japanese patients with solid tumors
NCT03499444Phase 1Completed
- Sponsor
- pharma&
- Start
- Feb 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rucaparib in solid tumor, ovarian cancer and breast cancer, sponsored by pharma&. Primary endpoints: Number of participants with treatment-related Adverse Events at 12 months, Number of participants with serious Adverse Events at 12 months and 1 more. Started Feb 2018; status: completed.
02
Drugs
rucaparib
03
Conditions
solid tumorovarian cancerbreast cancer
Beyond the preview
Go deeper on NCT03499444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03499444.